ENTA

Enanta Pharmaceuticals, Inc.

66.46
USD
-2.65%
66.46
USD
-2.65%
37.59 102.00
52 weeks
52 weeks

Mkt Cap 1.38B

Shares Out 20.22M

Chat
Send me real-time posts from this site at my email

Health Care Sector Update for 06/22/2022: ATHA, ENTA, BBIO, XLV, IBB

Health care stocks were declining premarket Wednesday. The Health Care SPDR (XLV) and the iShares NASDAQ Biotechnology Index (IBB) were down more than 1%. Athira Pharma (ATHA) was retreating by more than 69% after saying its phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease failed to meet both its primary and secondary endpoints. Enanta Pharmaceuticals (ENTA) said it filed suit in Massachusetts federal court seeking damages for Pfizer (PFE), alleging infringement of a patent in the production, sale, and use of Pfizer's Paxlovid COVID-19 antiviral treatment. Enanta Pharmaceuticals was recently up more than 2%. BridgeBio Pharma (BBIO) was marginally advancing after saying initial pharmacodynamic results from two participants dosed with its Canavan disease therapy demonstrated the drug is producing functional aspartoacylase enzyme and the company is on the "right track." The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue